Amedeo Smart

Free Medical Literature Service

 

Amedeo

Bacterial Infections and Mycoses
  Free Subscription

Articles published in
Lancet
    March 2024
  1. BURKI T
    Pivotal tuberculosis vaccine trial begins.
    Lancet. 2024;403:1125.
    >> Share

  2. BHARGAVA A, Bhargava M, Pai M
    Tuberculosis: a biosocial problem that requires biosocial solutions.
    Lancet. 2024 Mar 20:S0140-6736(24)00489-6. doi: 10.1016/S0140-6736(24)00489.
    >> Share

  3. BURKI T
    The great cholera vaccine shortage.
    Lancet. 2024;403:891-892.
    >> Share

  4. SUBBARAMAN R, Fielding K
    Putting technology to the test in tuberculosis care.
    Lancet. 2024;403:878-879.
    >> Share

    February 2024
  5. KIMBALL AB, Ravichandran S
    Secukinumab treatment of hidradenitis suppurativa: questions remain - Authors' reply.
    Lancet. 2024;403:617-618.
    >> Share

  6. ENDO M, Kami M
    Secukinumab treatment of hidradenitis suppurativa: questions remain.
    Lancet. 2024;403:617.
    >> Share

  7. MAUL JT, Kolios AGA, Thomsen SF, Ring HC, et al
    Secukinumab treatment of hidradenitis suppurativa: questions remain.
    Lancet. 2024;403:616-617.
    >> Share

  8. PETERS RPH, Klausner JD, Mazzola L, Mdingi MM, et al
    Novel lateral flow assay for point-of-care detection of Neisseria gonorrhoeae infection in syndromic management settings: a cross-sectional performance evaluation.
    Lancet. 2024;403:657-664.
    >> Share

  9. PAI NP, Dillon JR
    A lateral flow assay for Neisseria gonorrhoeae: a step forward for an inexpensive biomarker-based diagnosis of N gonorrhoeae at the point of care?
    Lancet. 2024;403:594-595.
    >> Share

    January 2024
  10. WEI X, Hicks JP, Zhang Z, Haldane V, et al
    Effectiveness of a comprehensive package based on electronic medication monitors at improving treatment outcomes among tuberculosis patients in Tibet: a multicentre randomised controlled trial.
    Lancet. 2024 Jan 31:S0140-6736(23)02270-5. doi: 10.1016/S0140-6736(23)02270.
    >> Share

  11. PATEL PD, Liang Y, Meiring JE, Chasweka N, et al
    Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.
    Lancet. 2024 Jan 25:S0140-6736(23)02031-7. doi: 10.1016/S0140-6736(23)02031.
    >> Share

  12. TADESSE BT, Cardona RSB, Marks F
    Long-term protection conferred by typhoid conjugate vaccines: a step towards typhoid elimination?
    Lancet. 2024 Jan 25:S0140-6736(23)02350-4. doi: 10.1016/S0140-6736(23)02350.
    >> Share

  13. CHICOINE N, Greenberg S
    Severe colonic distention and malnutrition in a 6-week-old infant: a case of Hirschsprung-associated enterocolitis.
    Lancet. 2024;403:282.
    >> Share

    November 2023
  14. SAMARASEKERA U
    Anurag and Madhavi Bhargava: enhancing TB prevention and care.
    Lancet. 2023;402:1740.
    >> Share

  15. WRENN K, Blomquist PB, Inzoungou-Massanga C, Olufon O, et al
    Surge of lower respiratory tract group A streptococcal infections in England in winter 2022: epidemiology and clinical profile.
    Lancet. 2023;402 Suppl 1:S93.
    >> Share

    October 2023
  16. MEMISH ZA, Blumberg L, Al-Maani AS, Baru R, et al
    Moving cholera vaccines ahead of the epidemic curve.
    Lancet. 2023 Oct 17:S0140-6736(23)02244-4. doi: 10.1016/S0140-6736(23)02244.
    >> Share

  17. BURKI T
    J&J patent decision to enable generic tuberculosis treatment.
    Lancet. 2023;402:1313.
    >> Share

    September 2023
  18. THE LANCET
    Tuberculosis: a different way of doing things.
    Lancet. 2023;402:937.
    >> Share

  19. REID M, Agbassi YJP, Arinaminpathy N, Bercasio A, et al
    Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis.
    Lancet. 2023 Sep 13:S0140-6736(23)01379-X. doi: 10.1016/S0140-6736(23)01379.
    >> Share

  20. BEKO B, Furin J
    Beyond individual inclusion, investment in affected communities is needed to end tuberculosis.
    Lancet. 2023 Sep 13:S0140-6736(23)01892-5. doi: 10.1016/S0140-6736(23)01892.
    >> Share

    August 2023
  21. NELSON R
    Syphilis rates soar in the USA amid penicillin shortage.
    Lancet. 2023;402:515.
    >> Share

  22. BHARGAVA A, Bhargava M, Meher A, Benedetti A, et al
    Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial.
    Lancet. 2023 Aug 8:S0140-6736(23)01231-X. doi: 10.1016/S0140-6736(23)01231.
    >> Share

  23. SINHA P, Mehta S
    Food: the tuberculosis vaccine we already have.
    Lancet. 2023 Aug 8:S0140-6736(23)01321-1. doi: 10.1016/S0140-6736(23)01321.
    >> Share

    July 2023
  24. PEELING RW, Mabey D, Chen XS, Garcia PJ, et al
    Syphilis.
    Lancet. 2023;402:336-346.
    >> Share

    May 2023
  25. RICHARD M, Amiens P, Arregle F, Courand PY, et al
    Myocardial calcification: a rare consequence of streptococcal toxic shock.
    Lancet. 2023;401:1691.
    >> Share

    April 2023
  26. HAWKEY C
    Helicobacter pylori eradication and aspirin: a puzzle yet to be solved - Author's reply.
    Lancet. 2023;401:1266.
    >> Share

  27. GATTA L, Zullo A, Vaira D
    Helicobacter pylori eradication and aspirin: a puzzle yet to be solved.
    Lancet. 2023;401:1265-1266.
    >> Share

  28. REID M, Yamey G, Goosby E, Jamison D, et al
    Seizing opportunities to end TB: a call for ambition and optimism on World TB Day.
    Lancet. 2023;401:1153.
    >> Share

    March 2023
  29. KIRBY T
    Ruvandhi Nathavitharana: advancing TB diagnostics and advocacy.
    Lancet. 2023;401:990.
    >> Share

  30. KASAEVA T, Dias HM, Pai M
    Fast-tracking progress to End TB: high-level opportunities for investment and action.
    Lancet. 2023;401:975-978.
    >> Share

  31. KEECH C, Miller VE, Rizzardi B, Hoyle C, et al
    Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus-diphtheria-acellular pertussis vaccine: a randomised, double-blind, phase 2b trial.
    Lancet. 2023;401:843-855.
    >> Share

  32. EDWARDS KM, Decker MD
    An alternative route to pertussis protection?
    Lancet. 2023;401:800-801.
    >> Share

  33. EGEBERG A, Thyssen JP
    The optimal biologic treatment target for hidradenitis suppurativa remains undiscovered.
    Lancet. 2023;401:708-710.
    >> Share

  34. KIMBALL AB, Jemec GBE, Alavi A, Reguiai Z, et al
    Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
    Lancet. 2023;401:747-761.
    >> Share

    February 2023
  35. BURKI T
    "Things have gone seriously wrong": global cholera surges.
    Lancet. 2023;401:633-634.
    >> Share

  36. AZIMINIA N, Soman B, Samoes J, Randhawa R, et al
    A diagnostic conundrum of a "ring of fire": a case of tuberculous perimyocarditis.
    Lancet. 2023;401:470-471.
    >> Share

    January 2023
  37. THOMPSON GR 3RD, Soriano A, Cornely OA, Kullberg BJ, et al
    Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.
    Lancet. 2023;401:49-59.
    >> Share

    December 2022
  38. DANIELS JP
    Cholera surges in Haiti.
    Lancet. 2022;400:1913.
    >> Share

    November 2022
  39. GUINEA J
    Rezafungin and invasive candida infections: a new game changing antifungal?
    Lancet. 2022 Nov 25:S0140-6736(22)02371-6. doi: 10.1016/S0140-6736(22)02371.
    >> Share


  40. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet. 2022 Nov 18:S0140-6736(22)02185-7. doi: 10.1016/S0140-6736(22)02185.
    >> Share

  41. GOODALL RL, Meredith SK, Nunn AJ, Bayissa A, et al
    Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial.
    Lancet. 2022 Nov 7. pii: S0140-6736(22)02078.
    >> Share

  42. DHEDA K, Lange C
    A revolution in the management of multidrug-resistant tuberculosis.
    Lancet. 2022 Nov 7. pii: S0140-6736(22)02161.
    >> Share

  43. HAWKEY C, Avery A, Coupland CAC, Crooks C, et al
    Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial.
    Lancet. 2022;400:1597-1606.
    >> Share

  44. LANAS A, Santilli F
    Aspirin and Helicobacter pylori interaction.
    Lancet. 2022;400:1560-1561.
    >> Share

  45. JACKSON S, Kabir Z, Comiskey C
    Impact of universal tuberculosis vaccination cessation on the epidemiology of paediatric tuberculosis cases in Ireland from 2011 to 2021.
    Lancet. 2022;400 Suppl 1:S53.
    >> Share

  46. JACKSON S, Kabir Z, Comiskey C
    Divergence in pace of decline in tuberculosis rates among migrants versus non-migrants in Ireland from 2011 to 2020.
    Lancet. 2022;400 Suppl 1:S52.
    >> Share

    October 2022
  47. WIECH T, Reinhard L, Wulf S, Giuffrida AE, et al
    Bacterial infection possibly causing autoimmunity: Tropheryma whipplei and membranous nephropathy.
    Lancet. 2022 Oct 31. pii: S0140-6736(22)02039.
    >> Share

  48. MOK J, Lee M, Kim DK, Kim JS, et al
    9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial i
    Lancet. 2022;400:1522-1530.
    >> Share

  49. REUTER A, Furin J
    Celebrating choice in the care of people living with drug-resistant tuberculosis.
    Lancet. 2022;400:1489-1491.
    >> Share

    September 2022
  50. DEVI S
    War driving cholera in Syria.
    Lancet. 2022;400:986.
    >> Share

    August 2022
  51. MARKS GB, Horsburgh CR Jr, Fox GJ, Nguyen TA, et al
    Epidemiological approach to ending tuberculosis in high-burden countries.
    Lancet. 2022 Aug 4. pii: S0140-6736(22)01433.
    >> Share

    May 2022
  52. COUSINS S
    Eliminating cholera in Haiti.
    Lancet. 2022;399:1928-1929.
    >> Share

    April 2022
  53. PIETER Y, Grijsen ML
    Picturing health: the burden of leprosy in eastern Indonesia.
    Lancet. 2022;399:1588-1599.
    >> Share

  54. KANUNGO S, Azman AS, Ramamurthy T, Deen J, et al
    Cholera.
    Lancet. 2022;399:1429-1440.
    >> Share

    March 2022
  55. DHEDA K, Pinto L, Mutsvangwa J, Leung CC, et al
    Accelerate investment and action to find the missing patients with tuberculosis.
    Lancet. 2022 Mar 22. pii: S0140-6736(22)00535.
    >> Share

  56. YAKOVENKO V, Brauner R, Votinov E, Goldfarb Y, et al
    Infective endocarditis and thromboses due to antiphospholipid syndrome following acute Q fever.
    Lancet. 2022;399:1154.
    >> Share

  57. WATTS G
    Alberto Garcia-Basteiro: seeking better TB control in Mozambique.
    Lancet. 2022;399:1109.
    >> Share

    February 2022
  58. KUMAR A, Preston N, Phillips R
    Picturing health: Buruli ulcer in Ghana.
    Lancet. 2022;399:786-797.
    >> Share

  59. HEINING D, Plant AJ
    Steroid use in non-pneumococcal and non-Haemophilus bacterial meningitis.
    Lancet. 2022;399:717-718.
    >> Share

  60. VAN DE BEEK D, Brouwer MC, Koedel U, Wall EC, et al
    Steroid use in non-pneumococcal and non-Haemophilus bacterial meningitis - Authors' reply.
    Lancet. 2022;399:718.
    >> Share

  61. BEYRER C
    Archbishop Desmond Tutu and the universality of health and human rights.
    Lancet. 2022;399:503-504.
    >> Share

    January 2022
  62. VIGNESHWARAN J, Kumar MS, Raghavan V, Sundari S, et al
    Seizures and sideroblastic anaemia in a patient with multidrug-resistant tuberculosis.
    Lancet. 2022;399:393.
    >> Share


  63. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.
    Lancet. 2022 Jan 18. pii: S0140-6736(21)02724.
    >> Share

  64. LAXMINARAYAN R
    The overlooked pandemic of antimicrobial resistance.
    Lancet. 2022 Jan 18. pii: S0140-6736(22)00087.
    >> Share

  65. MCCALL C
    Disrupted care in Papua New Guinea: the harms of COVID-19.
    Lancet. 2022;399:226-227.
    >> Share

    December 2021
  66. HOSSEINPOOR AR, Bergen N, Kirkby K, Schlotheuber A, et al
    Monitoring inequalities is a key part of the efforts to end AIDS, tuberculosis, and malaria.
    Lancet. 2021 Dec 8. pii: S0140-6736(21)02756.
    >> Share

    November 2021
  67. LANE R
    Pascale Ondoa: strengthening laboratory medicine in Africa.
    Lancet. 2021;398:1955.
    >> Share

    October 2021
  68. BUTLER-LAPORTE G, Halme A, Simard C
    Antibiotic treatment duration for bacteraemic pneumonia.
    Lancet. 2021;398:1485.
    >> Share

  69. DINH A
    Antibiotic treatment duration for bacteraemic pneumonia - Author's reply.
    Lancet. 2021;398:1485-1486.
    >> Share

  70. COUSSEMENT J, Dauby N
    Antibiotic treatment duration for bacteraemic pneumonia.
    Lancet. 2021;398:1484-1485.
    >> Share

  71. HEGDE A, Littlechild P, Taylor W
    Lumbar sediment sign seen in an unusual presentation of meningitis.
    Lancet. 2021;398:1436.
    >> Share

    September 2021
  72. LOW N, Hocking JS, van Bergen J
    The changing landscape of chlamydia control strategies.
    Lancet. 2021 Sep 22. pii: S0140-6736(21)02002.
    >> Share

  73. LANE R
    Gagandeep Kang: helping to shape a healthier India.
    Lancet. 2021;398:947.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016